AnuBio

We are a team of interdisciplinary scientists united by the common goal of finding novel and effective immunotherapies that outperform current standard of care for lung and skin cancer. Our diverse and combined experience allows us to embrace and tie together the robustness of recent scientific advances in tech-bio and the resilience of conventional drug development strategies. At AnuBio, we focus on closed-loop lab-AI drug discovery to reprogram immune responses by mapping the higher-order immune interactions. Our foundational model is also designed to derisk drug development by reliably predicting human clinical performance characteristics of lead candidates. Visit our website: https://anubio.ai/ We’d be delighted to address your questions and explore potential partnerships. Please contact us at: press@anubio.ai.